Trial Profile
Postmarketing Surveillance Study on the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis With Interferon Beta 1a (Rebif).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Dec 2018
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms TOURIMS
- Sponsors Merck KGaA
- 15 Jun 2010 New trial record